RITUXIMAB AS A TREATMENT OF COLLAPSING GLOMERULOPATHY

Back

E-Poster

https://storage.unitedwebnetwork.com/files/1099/33783685cdbcce362c294c1d989b44e4.pdf

Abstract Title

First Name *

Deissy Ivonne

Last Name *

Flores Valenzuela

Co-author 1

Jessica Itzel Lázaro Pérez jessicailp21@gmail.com Hospital de Especialidades ¨Dr. Antonio Fraga Mouret¨ del Centro Médico Nacional ¨La Raza Nephrology Ciudad de México

Co-author 2

Margarita Marlene Padilla-Morales marlene-040894@hotmail.com Hospital de Especialidades ¨Dr. Antonio Fraga Mouret¨ del Centro Médico Nacional ¨La Raza Nephrology Ciudad de México

Co-author 3

Fernando Jandete-Rivera jandete68@radiologo@gmail.com Hospital de Especialidades ¨Dr. Antonio Fraga Mouret¨ del Centro Médico Nacional ¨La Raza Interventional Radiology Ciudad de México

Co-author 4

Ma Virgilia Soto-Abraham virgiliasoto@gmail.com Instituto Nacional de Cardiología -Ignacio Chávez Pathological Anatomy3 Ciudad de México

Co-author 5

Luis Enrique Alvarez- Rangel luis.enrique.alvarez.rangel@gmail.com Hospital de Especialidades ¨Dr. Antonio Fraga Mouret¨ del Centro Médico Nacional ¨La Raza Nephrology Ciudad de México

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

INTRODUCTION: Collapsing glomerulopathy (CG) is characterized by massive proteinuria, frequently refractory to immunosuppressive therapy, with rapid progression to end-stage chronic kidney disease (ESRD). We present 3 cases of cFSGS treated with rituximab (RTX)

OBJECTIVE: To describe the response to treatment with two 1g doses of rituximab in three patients with collapsing glomerulopathy.

Methods

MATERIAL AND METHODS: Clinical records of 242 patients with a diagnosis of focal and segmental glomerulosclerosis treated at our hospital were reviewed. Patients with collapsing glomerulopathy not associated with HIV were identified. Clinical and laboratory characteristics were collected: serum creatinine, 24-hour urine proteinuria, serum albumin, rituximab dose, and treatment response using KDIGO criteria for partial, complete, or non-remission. The analysis was carried out with descriptive statistics.

Results

RESULTS: Three patients with collapsing glomerulopathy not associated with HIV who were treated with rituximab were identified. The age range was 22 to 66 years, all patients with massive proteinuria and deterioration of renal function. They received treatment with 1g of rituximab on days 1 and 15, used as the first line of treatment in 2 patients, and as the third line in 1 patient with corticosteroid resistance. One patient had complete remission and two patients had partial remission. In all cases there was an improvement in serum creatinine compared to baseline and an improvement in serum albumin.

Conclusions

CONCLUSIONS: Treatment with rituximab in patients with collapsing glomerulopathy appears to be a reasonable treatment option, even as first line.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos